VOOPOO
7.1.2022 13:02:14 CET | Business Wire | Press release
At the start of the new year 2022, VOOPOO , always in pursuit of unique industrial designs, has made another big move. On January 5, it launched Vinci Pod Royal Edition with a new relief design. Its shining and lightweight overall shape emphasizes a retro feel while also showing a strong aristocratic atmosphere.
Original relief craftsmanship for Pod
A large number of relief artworks have been unearthed from the ancient Sumerian Ruins, one of the birthplaces of human civilization. In contemporary times, there are also plenty of art products using relief craftsmanship. According to Vivian, Head of VOOPOO Product Development Team, “It is precisely the ancient relief artworks and the fashionable and retro contemporary elements that inspired us to develop the Vinci Pod Royal Edition series. Our original purpose is to explore the artistic and cultural value of the Pod product itself, so that users can also show their artistic taste in the process of using the product.”
However, it is no easy to engrave relief patterns on delicate Pod products. Any slight fault in the process will result in failure to achieve art-grade quality. The six products of the VOOPOO Vinci Pod Royal Edition series are all designed by experienced artists and are also integrated with design elements from retro jazz and cool graffiti styles. Product development took 8 months, and 12 manufacture processes and 68 techniques were involved, with 80% of the work completed by hand. The products were a result of the collaboration of more than 20 people including industrial designers, structural designers, and R&D members.
In addition to the unique relief itself, the tactile experience brought by the relief is even more impressive. Since the relief pattern of each product is different, customers can choose according to their own visual and tactile preferences. When the Pod of "tactile beauty" is held in your hand, you can experience an artistic masterpiece with its concave-convex surface, allowing you to enjoy a noble experience at your fingertip.
Focused on the user's product experience
In addition to the appearance, the product’s material and user experience also fit the users’ habits. The VOOPOO product development team has chosen the 6061 aviation-grade aluminum alloy, which boasts excellent strength, plasticity, fracture toughness, fatigue resistance, stress corrosion cracking resistance and exfoliation corrosion resistance, and has been widely used in aerospace, high-speed rail and automotive industries. It is worth noting that after 268 precise airflow experiments, the transmitter and airway design of VINCI Pod Royal Edition has been well optimized, bringing unparalleled comfort to the mouth-sucking experience.
VINCI Pod Royal Edition comes with the visual VINCI POD cartridge, which allows users to see the remaining e-liquid in real time, so that they can refill in time and refrain from anxiety. At the same time, VINCI Pod Royal Edition is equipped with 0.8Ω and 1.2Ω atomizers for users to enjoy different levels of taste and nicotine experience according to their preferences. VINCI Pod Royal Edition has also perfectly integrated the breathing light, so that it lights up when the user is inhaling, and goes off when stopping, providing users the strong dynamic sense.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
Voopoo website: https://www.voopoo.com/
IG: https://www.instagram.com/voopoo_global/
https://www.instagram.com/voopootechofficial/
Facebook: https://www.facebook.com/Voopootech/
Tiktok: https://www.tiktok.com/@voopoo_indonesia?lang=en
Please view the original press release at businesswire.com: https://www.businesswire.com/news/home/20220105006068/zh-CN/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom